Understanding BMI Thresholds for Wegovy and Saxenda Weight‑Loss Programs
When physicians consider prescribing a glucagon‑like peptide‑1 (GLP‑1) medication for obesity, the first gatekeeper is often the patient’s BMI (body mass index). Both Wegovy and Saxenda are FDA‑approved injectable GLP‑1 agonists that have shown meaningful weight loss in clinical trials, but their eligibility criteria differ slightly. In addition, insurers may apply their own rules, creating a layered landscape of BMI thresholds and coverage decisions.
What Is BMI and Why Does It Matter?
BMI is calculated by dividing a person’s weight in kilograms by the square of their height in meters (kg/m²). While it is a simple screening tool and not a diagnostic measure of body composition, BMI remains the standard metric used by regulatory agencies, clinicians, and insurers to define obesity and guide treatment pathways.
- Underweight: BMI < 18.5
- Normal weight: BMI 18.5 – 24.9
- Overweight: BMI 25 – 29.9
- Obesity Class I: BMI 30 – 34.9
- Obesity Class II: BMI 35 – 39.9
- Obesity Class III (Severe): BMI ≥ 40
Because GLP‑1 therapies target obesity, most payer policies start eligibility at the point where a person’s BMI indicates at least Class I obesity (≥ 30 kg/m²) or when a lower BMI is paired with obesity‑related comorbidities such as type 2 diabetes, hypertension, or dyslipidemia.
Wegovy: FDA‑Approved Indication and Standard BMI Thresholds
Wegovy (semaglutide 2.4 mg) received FDA approval in 2021 for chronic weight management. The label specifies two primary eligibility pathways:
- A BMI of **30 kg/m² or greater** (obesity) regardless of comorbidities.
- A BMI of **27 kg/m² or greater** **plus** at least one weight‑related condition (e.g., type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnea).
These thresholds are intentionally aligned with the pivotal STEP clinical trials, which demonstrated an average weight loss of roughly 15 % of body weight in participants meeting the above criteria. The trials also included a small proportion of participants with a BMI between 27 and 30 who had comorbidities, reflecting the real‑world patient mix.
Saxenda: FDA‑Approved Indication and Standard BMI Thresholds
Saxenda (liraglutide 3.0 mg) was approved earlier, in 2014, for chronic weight management. Its label outlines the following eligibility conditions:
- A BMI of **30 kg/m² or greater** (obesity) without the need for additional comorbidities.
- A BMI of **27 kg/m² or greater** **plus** at least one obesity‑related comorbidity (such as type 2 diabetes, dyslipidemia, hypertension, or obstructive sleep apnea).
The pivotal SCALE trials for Saxenda reported an average weight loss of about 8‑10 % of baseline weight, a figure that is modestly lower than Wegovy’s outcomes but still clinically meaningful, especially for patients who may not tolerate the higher dose of semaglutide.
Key Differences Between Wegovy and Saxenda Eligibility
While the BMI thresholds for both drugs appear identical on paper, subtle distinctions affect real‑world access:
- Dose and Administration: Wegovy is administered once weekly at a higher dose, whereas Saxenda is a daily injection at a lower dose. Some insurers consider the dosing schedule when determining coverage.
- Clinical Trial Data: Wegovy’s larger weight‑loss results have prompted many payers to prioritize it for patients with higher BMI or more severe comorbidities.
- Formulary Placement: Certain health plans place Saxenda on a lower tier (higher copay) while reserving Wegovy for patients who meet stricter criteria, such as BMI ≥ 35 kg/m².
How Insurers Interpret BMI Thresholds
Insurance companies translate the FDA label into policy language, and these translations can vary widely:
Private Commercial Plans
Many commercial insurers follow the FDA’s two‑step framework but add “step therapy” requirements. For example:
- If a patient’s BMI is between 27 and 30 kg/m² with a comorbidity, the plan may first require a trial of a lower‑cost GLP‑1 (e.g., Saxenda) before approving Wegovy.
- Patients with BMI ≥ 35 kg/m² often receive direct approval for Wegovy, bypassing step therapy.
Medicare Advantage & Medicaid
Medicare Advantage plans typically align closely with the FDA label, but some state Medicaid programs impose additional documentation, such as recent laboratory results or specialist referrals, especially for patients with BMI 27‑30 kg/m².
Employer‑Sponsored Health Plans
Employer plans may negotiate their own formulary tiers. In some large employers, Saxenda is listed as a “preferred” drug for BMI 30‑34.9 kg/m², while Wegovy is reserved for BMI ≥ 35 kg/m² or for patients with type 2 diabetes who have not achieved glycemic targets with other agents.
Impact of Comorbidities
When a comorbidity is present, insurers often relax the BMI requirement to 27 kg/m². However, the definition of a qualifying comorbidity can differ. For instance:
- Some plans accept only type 2 diabetes or hypertension.
- Others broaden the list to include non‑alcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS), or a history of cardiovascular events.
Other GLP‑1 Options: Ozempic, Mounjaro, and Zepbound
Although Ozempic (semaglutide 0.5 mg or 1 mg) is primarily indicated for type 2 diabetes, many clinicians prescribe it off‑label for weight loss. Because Ozempic is not FDA‑approved for obesity, most insurers require a documented diabetes diagnosis and do not apply the same BMI thresholds used for Wegovy.
Mounjaro (tirzepatide) and Zepbound (tirzepatide 15 mg) are newer agents that have demonstrated impressive weight‑loss outcomes in the SURPASS and STEP‑2 trials. As of mid‑2024, they are still pending FDA approval for obesity, so eligibility criteria remain in flux and are generally more restrictive, often limited to clinical trial enrollment or compassionate‑use programs.
Practical Tips for Patients Navigating BMI Eligibility
- Know Your Numbers: Calculate your BMI using a reputable online calculator and keep a record of your latest height and weight measurements.
- Document Comorbidities: Gather recent lab reports, blood pressure readings, and any specialist notes that confirm the presence of obesity‑related conditions.
- Check Your Plan’s Formulary: Look up the specific GLP‑1 coverage details for your health insurance. Many plans publish tiered drug lists on their websites.
- Ask About Step Therapy: If your plan requires a trial of a lower‑cost medication first, ask your provider whether a documented trial has been completed.
- Consider an Online Provider: Licensed telehealth services can streamline the eligibility verification process, especially for patients who live in areas with limited endocrinology access.
Getting Started with GLP-1
Embarking on a GLP‑1 weight‑loss program begins with confirming that you meet the BMI thresholds and any additional comorbidity requirements of your insurer. A licensed online provider can review your medical history, calculate your BMI, and submit the necessary documentation to your health plan—all from the comfort of your home. If you’re ready to see whether you qualify for Wegovy, Saxenda, or another GLP‑1 option, you can check your eligibility here.
Frequently Asked Questions
1. Can I qualify for Wegovy if my BMI is below 30 kg/m²?
Yes, if you have at least one obesity‑related comorbidity (e.g., type 2 diabetes, hypertension, high cholesterol). In that case, the threshold drops to a BMI of 27 kg/m², but insurers may still require additional documentation.
2. Is Saxenda covered for patients with a BMI of 28 kg/m² without comorbidities?
Generally, no. Most plans follow the FDA label, which stipulates that a BMI of 27 kg/m² or higher must be paired with a qualifying comorbidity. Without a comorbidity, the minimum BMI for coverage is 30 kg/m².
3. How do step‑therapy requirements affect my ability to get Wegovy?
Step therapy may require you to try a lower‑cost GLP‑1 (often Saxenda) first. If you have a BMI ≥ 35 kg/m² or a documented lack of response to the initial therapy, many insurers will approve Wegovy without further delay.
4. Do insurance plans treat Ozempic differently from Wegovy for weight loss?
Yes. Ozempic is approved for diabetes, not obesity, so insurers typically only cover it when a diabetes diagnosis is present. Wegovy’s coverage is tied directly to the obesity indication and follows the BMI thresholds described above.
Medical Disclaimer: This article provides general information and does not constitute medical advice. Always consult a qualified healthcare professional before starting or changing any medication regimen. Coverage decisions and eligibility criteria may vary by insurer and are subject to change.